Open Access
Table 2.
Baseline data of the study population.
| Patient | 28 | ||
| Gender: Male/Female | 12/16 | ||
| Age: mean (range) |
53 (18–79) |
||
| Laboratory results |
Mean (range) |
Normal range of value |
Number of patients with value outside the range |
| AST | 35 (12–290) | 5–42 U/L | 1 |
| ALT | 30 (8–192) | 10–40 U/L | 4 |
| ALP | 266 (30–1895) | 40–129 U/L | 12 |
| GGT | 105 (20–530) | 5–85 U/L | 10 |
| LDH | 365 (153–658) | 135–250 U/L | 21 |
| Total Bilirubin | 1.06 (0.2–14) | 0.2–1 mg/dL | 4 |
| Direct Bilirubin | 0.74 (0.01–13.39) | 0–0.3 mg/dL | 4 |
| Total Protein | 7.64 (6.3–8.7) | 6.4–8.3 g/dL | 5 |
| AFP | 7.78 (0.9–94.55) | <13.6 ng/mL | 1 |
| CEA | 2.06 (0.23–6.19) | <5 ng/mL | 1 |
| CA 19-9 | 18.6 (2.3–73) | 0–34 U/mL | 1 |
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, GGT: Gamma-glutamyl transpeptidase, LDH: Lactate dehydrogenase, AFP: Alpha-fetoprotein, CEA: Carcinoembryonic antigen, CA 19-9: Cancer antigen 19-9.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.